ASCO 2025: Focus on Treatment Sequencing in mBC

William J. Gradishar, MD, Northwestern University Feinberg School of Medicine, shares his expert insights on the evolving treatment landscape for HER2-positive metastatic breast cancer. In this discussion, he explores the potential impact of DESTINY-Breast09 and the combination of trastuzumab deruxtecan (T-DXd) with pertuzumab as a first-line option, comparing it to the long-standing THP regimen. Dr. Gradishar also weighs in on sequencing strategies, the role of antibody-drug conjugates (ADCs), and the clinical importance of tailoring treatment based on toxicity profiles and patient-specific factors.